Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic.
Canuti M, Monti MC, Bobbio C, Muscatello A, Muheberimana T, Baldi SL, Blasi F, Canetta C, Costantino G, Nobili A, Peyvandi F, Tettamanti M, Villa S, Aliberti S, Raviglione MC, Gori A, Bandera A; COVID-19 Network Study Group. Canuti M, et al. Among authors: peyvandi f. Front Med (Lausanne). 2023 Sep 7;10:1260950. doi: 10.3389/fmed.2023.1260950. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37746083 Free PMC article.
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy.
Lombardi A, Villa S, Colaneri M, Scaglione G, Bai F, Varisco B, Bono V, Vena A, Dentone C, Russo C, Tettamanti M, Renisi G, Viero G, Azzarà C, Mantero M, Peyvandi F, Bassetti M, Marchetti G, Muscatello A, Nobili A, Gori A, Bandera A; “COVID 19 NETWORK”. Lombardi A, et al. Among authors: peyvandi f. J Infect Public Health. 2024 Mar;17(3):467-473. doi: 10.1016/j.jiph.2023.12.026. Epub 2024 Jan 17. J Infect Public Health. 2024. PMID: 38262085 Free article.
Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients.
Capecchi M, De Leo P, Abbattista M, Mancini I, Agosti P, Biganzoli M, Suffritti C, Ferrari B, Lecchi A, La Marca S, Padovan L, Scalambrino E, Clerici M, Tripodi A, Artoni A, Gualtierotti R, Peyvandi F. Capecchi M, et al. Among authors: peyvandi f. Haematologica. 2023 Nov 1;108(11):3152-3155. doi: 10.3324/haematol.2022.282478. Haematologica. 2023. PMID: 36951158 Free PMC article. No abstract available.
Anti-emicizumab antibodies do not cross-react with mim8 in vitro.
Valsecchi C, Gualtierotti R, Arcudi S, Ciavarella A, Siboni SM, Schiavone L, Beeg M, Gobbi M, Peyvandi F. Valsecchi C, et al. Among authors: peyvandi f. Res Pract Thromb Haemost. 2023 Aug 8;7(6):102161. doi: 10.1016/j.rpth.2023.102161. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37694267 Free PMC article. No abstract available.
COVID-19. Comparison of D-dimer levels measured with 3 commercial platforms.
Scalambrino E, Clerici M, Scardo S, Capecchi M, Della Noce C, Testa S, Peyvandi F, Tripodi A. Scalambrino E, et al. Among authors: peyvandi f. Res Pract Thromb Haemost. 2023 Nov 2;7(8):102247. doi: 10.1016/j.rpth.2023.102247. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193049 Free PMC article. No abstract available.
Erratum to 'A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.' [Research and Practice in Thrombosis and Haemostasis Volume 7, Issue 3, March 2023, 100139].
Colpani P, Baronciani L, Stufano F, Cozzi G, Boscarino M, Pagliari MT, Biguzzi E, Peyvandi F. Colpani P, et al. Among authors: peyvandi f. Res Pract Thromb Haemost. 2023 Jul 8;7(5):102141. doi: 10.1016/j.rpth.2023.102141. eCollection 2023 Jul. Res Pract Thromb Haemost. 2023. PMID: 37601023 Free PMC article.
726 results